The results of the trial suggested that the drug showed improvement in overall survival as comparison to placebo and has also demonstrated reduction in risk of mortality.
The trial evaluated around 172 patients with refractory metastatic colorectal cancer who had received standard chemotherapy at least two or more regimens containing a fluoropyrimidine, irinotecan, and oxaliplatin.